Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 17/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3599746 | 0.71 | ALDH1A1 (0.40) | SMN1; SMN2ALDH1A1GAAPPARG | |
| SCHEMBL3606243 | 0.71 | ALDH1A1 (0.40) | SMN1; SMN2ALDH1A1GAAPPARG | |
| SCHEMBL3599634 | 0.70 | ALDH1A1 (0.39) | SMN1; SMN2ALDH1A1GAAPPARG | |
| SCHEMBL3610769 | 0.70 | SMN1; SMN2 (0.35) | SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL3603499 | 0.69 | ALDH1A1 (0.38) | SMN1; SMN2ALDH1A1GAAPPARG | |
| SCHEMBL3613880 | 0.69 | ALDH1A1 (0.36) | SMN1; SMN2ALDH1A1GAAPPARG | |
| SCHEMBL3615104 | 0.69 | ALDH1A1 (0.36) | SMN1; SMN2ALDH1A1GAAPPARG | |
| SCHEMBL3601746 | 0.68 | ALDH1A1 (0.37) | SMN1; SMN2ALDH1A1GAAPPARG | |
| SCHEMBL3615618 | 0.68 | ALDH1A1 (0.37) | SMN1; SMN2ALDH1A1GAAPPARG | |
| SCHEMBL3596017 | 0.66 | PPARG (0.39) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016396-A1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128138-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016396-A1 | PYRAZOLE COMPOUND | SLC5A1, SLC5A2, GLP1R | SMN1; SMN2 4515/4885ALDH1A1 365/4885GAA 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.